Vertex highlights first oral presentation of phase 3 clinical data of the vanza triple and new data on long-term impact of trikafta® at the north american cystic fibrosis conference

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced the first accepted medical presentations of the phase 3 data on the investigational once daily vanzacaftor/tezacaftor/deutivacaftor (“vanza triple”) — the potential next-in-class triple combination medicine — will take place at the north american cystic fibrosis conference (nacfc). vertex also announced presentations describing long-term outcomes in people with cystic fibrosis (cf) ages 2 to 11 years tak.
VRTX Ratings Summary
VRTX Quant Ranking